Kardiocentrum Nitra s.r.o.
- Address
- lock Available on a paid plan
Cardiovascular Disease Prevention
The Kardiocentrum Nitra s.r.o. cardiology department is dedicated to reducing major adverse cardiovascular events in patients with established disease or high risk, using innovative lipid‑lowering strategies.
- Evaluation of a novel siRNA therapy to lower LDL‑cholesterol and prevent heart attacks and strokes
- Assessment of a monoclonal antibody targeting PCSK9 for enhanced cardiovascular protection
- Investigation of an antisense oligonucleotide that reduces lipoprotein(a) to cut long‑term event rates
Across nine trials, 22 investigators are exploring these approaches to improve outcomes for individuals with atherosclerotic disease, highlighting the site’s role in advancing preventive cardiology.
Heart Failure and Renal Comorbidity
Research at the centre focuses on patients with chronic heart failure, especially those whose kidney function is compromised, aiming to find therapies that lower hospitalization and mortality.
- Comparison of a dual‑acting renal‑protective agent combined with a SGLT2 inhibitor versus standard SGLT2 therapy
- Dose‑finding study of a novel oral compound intended to reduce NT‑proBNP levels in reduced‑ejection‑fraction heart failure
- Evaluation of a new medication targeting neurohormonal pathways to improve cardiac biomarkers
The trials involve patients with recent heart‑failure events and aim to demonstrate superior efficacy in reducing cardiovascular death and heart‑failure admissions.
Acute Myocardial Infarction Interventions
The site conducts studies on immediate treatment strategies for patients experiencing an anterior ST‑elevation myocardial infarction, seeking to improve survival and limit heart damage.
- Randomized assessment of an intravenous agent administered during primary PCI for STEMI
- Investigation of a short‑term therapy to lower post‑infarction mortality and rehospitalization rates
These investigations are part of a broader effort to refine acute coronary care and reduce long‑term complications after heart attacks.
Emerging RNA‑Based Therapies and Hypertension Management
A subset of trials explores cutting‑edge RNA‑targeted medicines and novel peptide inhibitors to control blood pressure and cardiovascular risk in patients with uncontrolled hypertension.
- Study of a small‑interfering RNA designed to lower systolic blood pressure and related cardiovascular events
- Evaluation of a peptide that modulates renin‑angiotensin pathways for resistant hypertension
By enrolling individuals with high cardiovascular risk, these studies aim to expand therapeutic options beyond traditional antihypertensive drugs.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 118 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 114 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Novartis Pharma AG2active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG10trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Kardiocentrum Nitra s.r.o.
lock Showing 1 of 39 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 118 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 3 | Unknown | 2024-04-19 | 2024-07-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.